Prostate Cancer Coverage from Every Angle

Michael J. Morris, MD, on PSMA-Targeted Imaging for Prostate Cancer: CONDOR Trial

Posted: Tuesday, June 30, 2020

Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses the feasibility of switching to PSMA-targeted imaging based on results from the CONDOR study, which showed the method could detect and localize occult disease in most men with biochemically recurrent prostate cancer who presented with negative or equivocal conventional imaging findings.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.